| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director
2 companies
Jane Wasman is Director at SLS, with reported holdings spanning 2 companies. Jane Wasman's net worth is not public. Form 4 filings only show shares in the companies where this person is an insider; those holdings are worth an estimated $1.7M at current prices.
Jane Wasman's largest disclosed position is in RIGL as Director, worth about $892K.
Jane Wasman has 20 Form 4 filings on record from March 2018 to May 2026, across 2 companies: Director at Rigel Pharmaceuticals (RIGL), 2019–2026; Director at SELLAS Life Sciences Group (SLS), 2018–2026.
The 29 reported transactions were 17 option or other derivative awards, 11 stock awards and 1 open-market purchase.
Counted by filing, the open-market trades come to 1 purchase worth about $34K and no sales.
The only open-market purchase was 20,000 shares of SLS at an average $1.69 on May 30, 2025, about $34K. Twelve months later SLS was up 444%.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| May 30, 2025 | SLS Sellas Life Sciences Group, Inc. | Director | Buy | 20,000 | $1.69 | $33,800.00 | +192.3% | +12.3% | +444.4% |